Latest Articles

Publication Date
GnRH agonist pretreatment in hormonal endometrial preparation: a comparison of two protocols for frozen embryo transfer outcomes.

The aim of this study was to compare the effects of different endometrial treatment regimens on the outcome of frozen embryo transfer (FET).

Published: Oct. 1, 2025, midnight
Deep pelvic endometriosis: clinical features, diagnosis, and treatment - a comprehensive review.

Deep infiltrative endometriosis (DIE) is characterized by the infiltration of endometrial tissue into the pelvic organs, such as the rectovaginal septum, utero-ovarian, and uterosacral ligaments. Bowel involvement occurs in approximately …

Published: Sept. 30, 2025, midnight
Cost-effectiveness of dienogest compared to gonadotropin releasing hormone agonists for the management of endometriosis in Vietnam.

Endometriosis-related dysmenorrhea and pelvic pain impose significant economic and quality-of-life burdens. This study evaluated the cost-effectiveness of dienogest compared to gonadotropin-releasing hormone agonists (GnRH-a) for managing dysmenorrhea and pelvic pain …

Published: Sept. 29, 2025, midnight
Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review.

Alarelin acetate, a synthetic gonadotropin-releasing hormone (GnRH) analogue, is widely used to manage endometriosis and hormone-sensitive malignancies. Although its safety profile is generally favorable, we report the first documented case …

Published: Sept. 29, 2025, midnight
The role of pre-operative gonadotrophin-releasing hormone agonists (GnRHa) on pain, bowel and bladder symptoms in rectovaginal/colorectal endometriosis surgery: a multicenter cohort study.

The efficacy of medical and surgical treatment of endometriosis-associated pain is a source of ongoing controversy. There is a lack of evidence about gonadotropin-releasing hormone agonists (GnRHa) use on long-term …

Published: Sept. 23, 2025, midnight
Tolerability and Shared Decision-Making in the Hormonal Management of Endometriosis-Associated Pain.

Background: The management of endometriosis-associated pain has traditionally focused on analgesic efficacy. However, with high-level evidence demonstrating therapeutic equivalence among principal hormonal classes, the paradigm has shifted towards a patient-centred …

Published: Sept. 18, 2025, midnight
Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.

Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other …

Published: Sept. 7, 2025, midnight
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.

Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …

Published: Sept. 1, 2025, midnight
Safety of current strategies to manage moderate to severe pain in patients with endometriosis.

Medical therapy is crucial in the long-term management of endometriosis, and its clinical efficacy must be balanced with a favorable safety profile.

Published: Aug. 25, 2025, midnight
Natural Pregnancy Following Oocyte Retrieval in a Luteal-Phase Progestin-Primed Ovarian Stimulation (PPOS) Protocol With Concurrent Blastocyst Cryopreservation: A Case Report.

Ovarian stimulation is used in assisted reproductive technology to help infertile couples achieve pregnancy. Luteal-phase stimulation with progestin-primed ovarian stimulation (PPOS) is a practical approach, as it involves oral medication …

Published: Aug. 17, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!